Ophthalmology and Therapy最新文献

{"title":"Incidence of Corneal Graft Failure with Glaucoma Drainage Device Placement in the Anterior Chamber Compared to the Ciliary Sulcus.","authors":"Emmeline J Kim, Monica K Ertel, Jennifer L Patnaik, Maxwell Mayeda, Deidre St Peter, Galia A Deitz, Jeffrey R SooHoo, Mina B Pantcheva, Malik Y Kahook, Leonard K Seibold, Karen L Christopher, Cara E Capitena Young","doi":"10.1007/s40123-025-01145-8","DOIUrl":"10.1007/s40123-025-01145-8","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the rate of corneal graft failure in eyes with glaucoma drainage device (GDD) placed in the anterior chamber (AC) versus the ciliary sulcus (CS).</p><p><strong>Methods: </strong>This was a retrospective chart review of eyes with coexisting corneal transplant and GDD between January 2014 and December 2021 at an academic medical center. The primary outcome was incidence of corneal transplant failure. Groups were compared with logistic regression modeling utilizing generalized estimating equations with an unstructured correlation to account for patients with two eyes included. Adjusted odds ratios (OR) and 95% confidence limits were determined for the primary outcome. Kaplan-Meier curves were used to demonstrate the time to failure.</p><p><strong>Results: </strong>Among 58 eyes, the graft failure rate for GDDs placed in the AC versus CS was 42.5% and 10.5%, respectively (p = 0.05). Male patients had higher odds of failure, OR 3.5 (95% CI 1.1, 10.4, p = 0.03). Maximum intraocular pressure, topical carbonic anhydrase inhibitor use, and type of corneal graft were not significantly associated with failure. The Kaplan-Meier survival curve demonstrated higher corneal transplant failure probabilities for eyes with GDD in the AC versus CS (p = 0.06). GDD location, after adjusting for sex, was not significantly associated with failure, OR 3.0 (95% CI 0.8, 11.6, p = 0.10).</p><p><strong>Conclusions: </strong>Corneal transplant failure rates were four times higher in eyes with GDDs in the AC compared to the CS, but the difference was not statistically significant. Further studies with larger sample sizes and follow-up are needed to fully explore differences in failure rates by GDD placement.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1297-1309"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069204/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Latanoprostene Bunod 0.024% Early Experience Program (LEEP): A Canadian Initiative for Open-Angle Glaucoma and Ocular Hypertension.","authors":"David Yan, Cindy M L Hutnik, Paul Harasymowycz","doi":"10.1007/s40123-025-01132-z","DOIUrl":"10.1007/s40123-025-01132-z","url":null,"abstract":"<p><strong>Introduction: </strong>Here we report the intraocular pressure (IOP) changes following treatment with latanoprostene bunod (LBN) 0.024% in patients in Canadian ophthalmology practices.</p><p><strong>Methods: </strong>This real-world, open-label, 6-week, observational study collected data from 59 Canadian ophthalmologists and a total of 653 patients. Eligibility was open to all patients treated with LBN 0.024% instilled once daily for open-angle glaucoma or ocular hypertension. IOP was assessed prior to initiating LBN and after a planned 6 weeks of treatment. Patient demographics, prior treatment(s), IOP, and patient/physician satisfaction ratings were recorded. Subgroup analyses included (1) patients naïve to prior IOP-lowering medication (with or without prior selective laser trabeculoplasty [SLT]) initiating LBN; (2) patients switching from a pre-existing medication to LBN; and (3) patients adding LBN to existing medications.</p><p><strong>Results: </strong>Of 653 patients included, 251 were naïve to previous medical antihypertensive therapy, 369 were switched to LBN from a previous medication, and 26 added LBN on top of existing medications (seven patients did not indicate status). Mean baseline IOP was 19.5 mmHg in the overall cohort and follow-up occurred over a period of 37.9 ± 7.9 days. Mean IOP was reduced by 16.3% (95% confidence interval 14.9-17.7) across all included patients. Overall IOP reduction from baseline was largest for naïve patients with no prior SLT (29.3%), with age and baseline IOP key determinants of outcomes in this group. Patient and physician satisfaction scores were high.</p><p><strong>Conclusion: </strong>This initial Canadian clinical experience of LBN in diverse patient and physician populations reflected its use in a real-world context, and demonstrated a significant IOP-lowering effect with LBN across patient groups seen in routine practice. Patient and physician satisfaction scores were high and in notable agreement.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1311-1323"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144035253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural and Functional Insight into Intracameral Cefuroxime Ocular Toxic Syndrome (ICOTS) in Eyes with Disrupted Intraocular Barrier.","authors":"Andrea Cusumano, Marco A Pileri, Benedetto Falsini, Massimo Cesareo, Michele D'Ambrosio, Fabian D'Apolito, Francesco Martelli, Marco Lombardo","doi":"10.1007/s40123-025-01137-8","DOIUrl":"10.1007/s40123-025-01137-8","url":null,"abstract":"<p><strong>Introduction: </strong>Intracameral cefuroxime is commonly used as a prophylaxis against endophthalmitis following cataract surgery. While its effectiveness is well-documented, concerns remain regarding potential toxicity. Intracameral cefuroxime ocular toxic syndrome (ICOTS) is characterized by acute, extensive, and serous retinal detachment that usually resolves spontaneously. However, the long-term effects of ICOTS have not yet been studied. This study aims to provide new insights into ICOTS using multimodal imaging, retinal electrophysiology, and perimetry to assess both acute and chronic functional and structural changes in eyes with a disrupted intraocular vitreous barrier.</p><p><strong>Methods: </strong>This retrospective case series included four patients affected by ICOTS who underwent cataract surgery with standard-dose intracameral cefuroxime (1.0 mg/0.1 ml). Three patients had previously undergone pars-plana vitrectomy and one patient had undergone anterior vitrectomy. Patients were followed up to 1 year after surgery. Evaluations included optical coherence tomography (OCT), ultra-wide-field (UWF) OCT-angiography (OCTA), automated perimetry, and multifocal electroretinography (ERG) at the preoperative visit (T0) and at 1 day (T1), 1 week (T2), 1 month (T3), 6 months (T4), and 1 year (T5) after cataract surgery.</p><p><strong>Results: </strong>At T1, all patients had acute extensive serous retinal detachments. UWF-OCTA revealed increased superficial vessel density during the acute phase, with only partial restoration at follow-up. Two cases had permanent structural damage to the outer retina. Functional assessments showed transient changes in multifocal ERG responses, returning to near-normal levels within T3. Best-corrected visual acuity worsened at T1 and improved after the subretinal fluid resolution (T2).</p><p><strong>Conclusion: </strong>Intracameral cefuroxime ocular toxic syndrome may induce persistent retinal changes despite fluid resolution in eyes with a disrupted intraocular barrier due to prior vitrectomy. Early OCT assessment can help to identify this condition. Further investigation, incorporating UWF-OCTA and ERG for a comprehensive assessment of ICOTS, along with revised informed consent protocols for patients undergoing cataract surgery with this antibiotic prophylaxis, may be indicated when risk factors are identified.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1337-1347"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Large Language Models: Pioneering New Educational Frontiers in Childhood Myopia.","authors":"Mohammad Delsoz, Amr Hassan, Amin Nabavi, Amir Rahdar, Brian Fowler, Natalie C Kerr, Lauren Claire Ditta, Mary E Hoehn, Margaret M DeAngelis, Andrzej Grzybowski, Yih-Chung Tham, Siamak Yousefi","doi":"10.1007/s40123-025-01142-x","DOIUrl":"10.1007/s40123-025-01142-x","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to evaluate the performance of three large language models (LLMs), namely ChatGPT-3.5, ChatGPT-4o (o1 Preview), and Google Gemini, in producing patient education materials (PEMs) and improving the readability of online PEMs on childhood myopia.</p><p><strong>Methods: </strong>LLM-generated responses were assessed using three prompts. Prompt A requested to \"Write educational material on childhood myopia.\" Prompt B added a modifier specifying \"a sixth-grade reading level using the FKGL (Flesch-Kincaid Grade Level) readability formula.\" Prompt C aimed to rewrite existing PEMs to a sixth-grade level using FKGL. Reponses were assessed for quality (DISCERN tool), readability (FKGL, SMOG (Simple Measure of Gobbledygook)), Patient Education Materials Assessment Tool (PEMAT, understandability/actionability), and accuracy.</p><p><strong>Results: </strong> ChatGPT-4o (01) and ChatGPT-3.5 generated good-quality PEMs (DISCERN 52.8 and 52.7, respectively); however, quality declined from prompt A to prompt B (p = 0.001 and p = 0.013). Google Gemini produced fair-quality (DISCERN 43) but improved with prompt B (p = 0.02). All PEMs exceeded the 70% PEMAT understandability threshold but failed the 70% actionability threshold (40%). No misinformation was identified. Readability improved with prompt B; ChatGPT-4o (01) and ChatGPT-3.5 achieved a sixth-grade level or below (FGKL 6 ± 0.6 and 6.2 ± 0.3), while Google Gemini did not (FGKL 7 ± 0.6). ChatGPT-4o (01) outperformed Google Gemini in readability (p < 0.001) but was comparable to ChatGPT-3.5 (p = 0.846). Prompt C improved readability across all LLMs, with ChatGPT-4o (o1 Preview) showing the most significant gains (FKGL 5.8 ± 1.5; p < 0.001).</p><p><strong>Conclusions: </strong>ChatGPT-4o (o1 Preview) demonstrates potential in producing accurate, good-quality, understandable PEMs, and in improving online PEMs on childhood myopia.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1281-1295"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of a New Virtual Program for Patients Overdue for Diabetic Retinopathy Evaluation.","authors":"Shannan G Moore, Daniel X Chen, Munish Sharma, Rudy Hedayi, Donald S Fong, Bobeck S Modjtahedi","doi":"10.1007/s40123-025-01136-9","DOIUrl":"10.1007/s40123-025-01136-9","url":null,"abstract":"<p><strong>Introduction: </strong>Diabetic retinopathy (DR) is one of the leading causes of preventable blindness in adults. Teleophthalmology for DR screening is becoming more prevalent; however, most programs are focused on baseline screening rather than screening and monitoring patients with established higher degrees of retinopathy. This study evaluated the incidence of detected ocular disease in a new virtual care program focused on assessing patients with a known history of retinopathy who were overdue for follow-up.</p><p><strong>Methods: </strong>A retrospective cohort study was performed on Kaiser Permanente Southern California patients with a prior diagnosis of DR who were at least 1 year overdue for their retinopathy assessment. The new virtual care program consisted of a scheduled technician visit where vision, intraocular pressure, macular optical coherence tomography (OCT), and ultrawide-field retinal photographs were taken and then remotely interpreted by a centralized clinical reading center. Patients who had a detected abnormality on imaging were referred to the clinic for further evaluation and management.</p><p><strong>Results: </strong>There were 790 patients enrolled in the program with an abnormality detected in 34.6% of patients. Of patients with a detected abnormality, 87.2% attended the recommended follow-up evaluation in the clinic. Concern for proliferative diabetic retinopathy (PDR) was the most common abnormality detected on imaging (10.3% of eyes). Treatments were administered to 27.2% of eyes that attended clinic evaluation following an abnormal screening result.</p><p><strong>Conclusion: </strong>Expanded teleophthalmology pathways can help achieve timely DR evaluation and increase access to care especially in vulnerable and medically underserved communities.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1271-1280"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069766/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-Year Outcomes of iStent inject Implantation With or Without Phacoemulsification in Eyes with Open-Angle Glaucoma.","authors":"Ricardo Augusto Paletta Guedes, Daniela Marcelo Gravina, Vanessa Maria Paletta Guedes, Daniel Augusto Guedes Moraes, Alfredo Chaoubah","doi":"10.1007/s40123-025-01134-x","DOIUrl":"10.1007/s40123-025-01134-x","url":null,"abstract":"<p><strong>Introduction: </strong>Minimally invasive glaucoma surgery (MIGS) has become more widespread in open-angle glaucoma (OAG) management. Broad evidence has shown a greater decrease in mean intraocular pressure (IOP) when cataract surgery is combined with MIGS, compared with cataract surgery alone. In this study, we evaluated the effectiveness and safety of second-generation trabecular micro-bypass implantation (iStent inject®) either in combination with cataract surgery (Combined subgroup) or as a standalone procedure (Standalone subgroup) in eyes with OAG. Our hypothesis was that implementing interventional glaucoma management would provide meaningful reductions in IOP and topical medication burden.</p><p><strong>Methods: </strong>This long-term retrospective consecutive case series included patients with mild to moderate OAG who received the iStent inject® Trabecular Micro-bypass stent with or without phacoemulsification between 2018 and 2024. Eligible patients were ≥ 18 years of age with mild or moderate OAG, cataract requiring surgery (for the Combined subgroup), and the need for IOP and/or medication reduction. Study outcomes included mean and proportional analyses of IOP and medications over time. Analyses were completed for the overall population and for the Combined/Standalone and Mild/Moderate subgroups.</p><p><strong>Results: </strong>The study included 271 eyes with mean age 69 years and a mean of 40 months of follow-up (range 10-79 months). In the overall population, mean IOP decreased from 16.4 mmHg at baseline to 13.7 mmHg at last follow-up (p = 0.001), while the mean number of medications decreased from 2.24 at baseline to 0.62 at last follow-up (p = 0.001). IOP reductions were also significant in the Combined/Standalone subgroups and in the Mild/Moderate subgroups (p = 0.001 for all), and all subgroups experienced increased proportions of eyes on no topical medications at last follow-up versus preoperative (p = 0.001 for all).</p><p><strong>Conclusion: </strong>This 5-year real-world study showed significant and sustained reductions in IOP and topical medication burden following iStent inject trabecular micro-bypass with or without cataract surgery in eyes with mild and moderate open-angle glaucoma.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"1219-1235"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069763/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143796130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustaining Ophthalmic Practices for the Future: A High-Value Care Approach to Environmental Responsibility.","authors":"Yee Ling Wong, Tariq M Aslam, David F Chang, Barbara Erny","doi":"10.1007/s40123-025-01146-7","DOIUrl":"10.1007/s40123-025-01146-7","url":null,"abstract":"<p><p>Ophthalmology, like all medical specialities, is continuously evolving to adapt to emerging challenges and advancements. The evidence-based medical practices that previously guided policies and regulations may no longer be sufficient or sustainable in the context of an ageing population, increasing healthcare demands, and the urgent need for sustainability. As the global burden on healthcare systems grows, sustainability must be considered from multiple perspectives, including financial and environmental aspects, without compromising patient outcomes. While financial sustainability is essential to ensure cost-effective resource allocation, accessibility, and affordability for both healthcare providers and patients, environmental sustainability is becoming an increasing priority. Efforts to minimise the carbon footprint associated with medical procedures, transportation, and the production and disposal of ophthalmic equipment and materials are necessary. This paper highlights key examples of areas within ophthalmology where sustainability can be enhanced by practicing high-value care. We describe targeted opportunities that demonstrate how sustainable practices can be successfully integrated into ophthalmology without compromising patient care or operational feasibility.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1199-1218"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144003881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epithelial Remodelling in Myopia After Keratorefractive Lenticule Extraction.","authors":"Maja Bohač, Ivan Gabrić, Sara Blazhevska, Mateja Jagić, Samuel Arba Mosquera","doi":"10.1007/s40123-025-01138-7","DOIUrl":"10.1007/s40123-025-01138-7","url":null,"abstract":"<p><strong>Introduction: </strong>We analyzed longitudinal epithelial changes after the treatment of myopia with keratorefractive lenticule extraction (KLEx) and the zonal change in epithelial thickness up to 12 months after SmartSight for myopic astigmatism with the SCHWIND ATOS femtosecond laser.</p><p><strong>Methods: </strong>We used anterior segment optical coherence tomography (AS-OCT) data and analyzed changes in the epithelium after treatment to ascertain how much epithelium hyperplasia occurred after KLEx. Data from 80 eyes treated with SmartSight, with a complete follow-up from postoperative day 1 (POD1) to 12 months postoperative, were used. The mean age of the patients was 29 ± 6 years with a mean spherical equivalent (SEQ) of - 4.72 ± 1.97 diopters (D) (- 1.25 to - 9.88 D) and a mean magnitude of refractive astigmatism of 0.90 ± 0.89 D. Preoperative central epithelial thickness was from 46 to 67 µm.</p><p><strong>Results: </strong>Postoperative central epithelial thickness at 12-month follow-up was 3 ± 5 µm thicker than preoperatively. The other epithelial zones (nasal, superior, temporal, inferior) thickened by + 4 ± 4 µm. The epithelial change showed larger variability at POD1 and stabilized from 1 week onwards. Postoperatively, the change in epithelium was not different for the different zones, and it did not correlate with the achieved refractive changes for any zone at any time point.</p><p><strong>Conclusions: </strong>The changes in epithelial thickness after KLEx for moderate myopia with SmartSight were minimal, indicating a low level of epithelial hyperplasia without resembling a regression-inducing lentoid. Findings suggest that KLEx with SCHWIND ATOS has a subtle impact on the epithelial thickness (with postoperative epithelium becoming slightly thicker). However, the differences remain below any clinical relevance.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1237-1247"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144033907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Evaluation of Biotrue Hydration Plus Multipurpose Solution in Daily Use with Planned Replacement Soft Contact Lenses.","authors":"Mark Schaeffer, Ayda Shahidi, Gary Mosehauer, Marjorie Rah, William Reindel","doi":"10.1007/s40123-025-01123-0","DOIUrl":"10.1007/s40123-025-01123-0","url":null,"abstract":"<p><strong>Introduction: </strong>Planned replacement soft contact lenses (PRSCLs) continue to remain a popular option for vision correction. Biotrue Hydration Plus (BHP) is a novel multipurpose solution (MPS) developed for PRSCLs, with a formulation informed by Tear Film & Ocular Surface Society (TFOS) International Dry Eye Workshop II insights. It contains hyaluronan (HA) for moisturizing, erythritol for antioxidant and osmoprotectant properties, and potassium to support ocular homeostasis. It also incorporates poloxamine 1107 and poloxamer 181 surfactants for lens cleaning and wettability, alongside a triple disinfectant system. A two-arm study evaluated the clinical performance of BHP MPS over 3 months; here, we present a subanalysis of the BHP MPS arm.</p><p><strong>Methods: </strong>This study was conducted across 17 sites in the USA, with evaluations at 2 weeks, 1 month, 2 months, and 3 months of lens wear. BHP MPS was dispensed to habitual wearers of silicone hydrogel or conventional hydrogel PRSCLs (four and one prespecified types, respectively). Subjects rated 13 lens performance attributes (grouped into comfort, vision, handling, lens cleanliness, and overall impression). Performance ratings were compared across visits using statistical methods to confirm consistency and equivalence. Investigators performed slit lamp examinations and evaluated lens deposits at each follow-up visit to assess MPS biocompatibility.</p><p><strong>Results: </strong>Mean scores for lens comfort, vision, handling, and cleanliness on removal, and also overall impression, were 80-100 across all visits (very good-excellent; p ≥ 0.05). No subject presented with > Grade 2 slit lamp findings at any visit, and few ungraded slit lamp findings were noted, reflecting the biocompatibility of BHP MPS with respect to the ocular surface. Lens deposition, cleanliness, and wettability were clinically acceptable in almost all subjects, and no participants discontinued owing to an adverse event.</p><p><strong>Conclusions: </strong>In this analysis, BHP MPS was associated with minimal lens deposition, excellent biocompatibility, and high-performance ratings, making it a promising option for PRSCL wearers and for eye care practitioners to recommend before switching symptomatic wearers to a different contact lens modality.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier NCT03897751.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1249-1260"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study.","authors":"Mekala Shellvarajah, Vuong Nguyen, Sarah Steinmann, Mark C Gillies, Alexandros Sagkriotis, Daniel Barthelmes","doi":"10.1007/s40123-025-01140-z","DOIUrl":"10.1007/s40123-025-01140-z","url":null,"abstract":"<p><strong>Introduction: </strong>The evolution of treatment patterns in neovascular age-related macular degeneration (nAMD) warrants investigation into the impact of patients' adherence to anti-vascular endothelial growth factor (VEGF) treatment on visual outcomes. This retrospective, non-randomized, non-comparative study aimed to investigate real-world adherence to anti-VEGF treatment.</p><p><strong>Methods: </strong>Patient (eyes) (≥ 50 years) with a diagnosis of nAMD who had a first injection of aflibercept or ranibizumab between January 2016 and December 2018 and 12 months of follow-up were included. Visual acuity (VA; logMAR letters) and duration of injection intervals were recorded. Adherence was defined as < 20% of visits deviating from the schedule by ≥ 14 days.</p><p><strong>Results: </strong>Overall, 133 patient eyes were included: 129 adherent, and four non-adherent. Mean (standard deviation) baseline VA was 57.0 (23.6) and 53.8 (35.3) letters in adherent and non-adherent patient eyes, respectively. Mean change in VA by month 12 was higher in adherent (6.3 letters) than non-adherent patient eyes (- 11 letters). Compared with the previous visit, adherent visits were associated with a mean increase in VA of 0.67 letters and non-adherent visits with a decrease of 2.30 letters.</p><p><strong>Conclusions: </strong>These results emphasize the importance of adherence to appropriate dosing regimens to optimize visual outcomes in patients with nAMD.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":"14 6","pages":"1261-1269"},"PeriodicalIF":2.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144021823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}